These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 16485916)

  • 1. Role of mechanistically-based pharmacokinetic/pharmacodynamic models in drug development : a case study of a therapeutic protein.
    Marshall S; Macintyre F; James I; Krams M; Jonsson NE
    Clin Pharmacokinet; 2006; 45(2):177-97. PubMed ID: 16485916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bridging the pharmacokinetics and pharmacodynamics of UK-279,276 across healthy volunteers and stroke patients using a mechanistically based model for target-mediated disposition.
    Jonsson EN; Macintyre F; James I; Krams M; Marshall S
    Pharm Res; 2005 Aug; 22(8):1236-46. PubMed ID: 16078133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part II. Population pharmacokinetic and pharmacodynamic modeling and simulation.
    Wiltshire HR; Kilpatrick GJ; Tilbrook GS; Borkett KM
    Anesth Analg; 2012 Aug; 115(2):284-96. PubMed ID: 22253270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetic modelling and estimation of dosing strategy for NXY-059, a nitrone being developed for stroke.
    Jönsson S; Cheng YF; Edenius C; Lees KR; Odergren T; Karlsson MO
    Clin Pharmacokinet; 2005; 44(8):863-78. PubMed ID: 16029070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and concentration-effect analysis of intravenous RGD891, a platelet GPIIb/IIIa antagonist, using mixed-effects modeling (NONMEM).
    Zannikos PN; Rohatagi S; Jensen BK; DePhillips SL; Rhodes GR
    J Clin Pharmacol; 2000 Oct; 40(10):1129-40. PubMed ID: 11028252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. UK-279,276, a neutrophil inhibitory glycoprotein, in acute stroke: tolerability and pharmacokinetics.
    Lees KR; Diener HC; Asplund K; Krams M;
    Stroke; 2003 Jul; 34(7):1704-9. PubMed ID: 12805489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of infusion rate on thiopental dose-response relationships. Assessment of a pharmacokinetic-pharmacodynamic model.
    Gentry WB; Krejcie TC; Henthorn TK; Shanks CA; Howard KA; Gupta DK; Avram MJ
    Anesthesiology; 1994 Aug; 81(2):316-24; discussion 25A. PubMed ID: 8053580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrated pharmacokinetics and pharmacodynamics in drug development.
    Dingemanse J; Appel-Dingemanse S
    Clin Pharmacokinet; 2007; 46(9):713-37. PubMed ID: 17713971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic-Pharmacodynamic Modelling of the antipyretic effect of two oral formulations of ibuprofen.
    Trocóniz IF; Armenteros S; Planelles MV; Benítez J; Calvo R; Domínguez R
    Clin Pharmacokinet; 2000 Jun; 38(6):505-18. PubMed ID: 10885587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
    Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
    Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biomarkers, validation and pharmacokinetic-pharmacodynamic modelling.
    Colburn WA; Lee JW
    Clin Pharmacokinet; 2003; 42(12):997-1022. PubMed ID: 12959633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours.
    Trocòniz IF; Garrido MJ; Segura C; Cendrós JM; Principe P; Peraire C; Obach R
    Cancer Chemother Pharmacol; 2006 Jun; 57(6):727-35. PubMed ID: 16261364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Semi-mechanistic autoinduction model of midazolam in critically ill patients: population pharmacokinetic analysis.
    Aoyama T; Hirata K; Yamamoto Y; Yokota H; Hayashi H; Aoyama Y; Matsumoto Y
    J Clin Pharm Ther; 2016 Aug; 41(4):392-8. PubMed ID: 27178380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetics of APOMINE: a meta-analysis in cancer patients and healthy males.
    Bonate PL; Floret S; Bentzen C
    Br J Clin Pharmacol; 2004 Aug; 58(2):142-55. PubMed ID: 15255796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetic-pharmacodynamic modelling of angiotensin receptor blockade in healthy volunteers.
    Csajka C; Buclin T; Fattinger K; Brunner HR; Biollaz J
    Clin Pharmacokinet; 2002; 41(2):137-52. PubMed ID: 11888333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of trabectedin (ET-743, Yondelis) induced neutropenia.
    Hing J; Perez-Ruixo JJ; Stuyckens K; Soto-Matos A; Lopez-Lazaro L; Zannikos P
    Clin Pharmacol Ther; 2008 Jan; 83(1):130-43. PubMed ID: 17597713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute Stroke Therapy by Inhibition of Neutrophils (ASTIN): an adaptive dose-response study of UK-279,276 in acute ischemic stroke.
    Krams M; Lees KR; Hacke W; Grieve AP; Orgogozo JM; Ford GA;
    Stroke; 2003 Nov; 34(11):2543-8. PubMed ID: 14563972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetic and pharmacodynamic modeling of transformed binary effect data of triflusal in healthy Korean male volunteers: a randomized, open-label, multiple dose, crossover study.
    Park SM; Lee J; Seong SJ; Park JG; Gwon MR; Lim MS; Lee HW; Yoon YR; Yang DH; Kwon KI; Han S
    BMC Pharmacol Toxicol; 2014 Dec; 15():75. PubMed ID: 25534747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma.
    Joerger M; Huitema AD; Meenhorst PL; Schellens JH; Beijnen JH
    Cancer Chemother Pharmacol; 2005 May; 55(5):488-96. PubMed ID: 15726371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The application of a Bayesian approach to the analysis of a complex, mechanistically based model.
    Jonsson F; Jonsson EN; Bois FY; Marshall S
    J Biopharm Stat; 2007; 17(1):65-92. PubMed ID: 17219756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.